Business
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
The NOD-like receptor protein 3 (NLRP3) inflammasome is a validated target for anti-inflammatory drug development. Upon activation by internal and external stimuli, NLRP3 mediates the release of proinflammatory cytokines IL-1β and IL-18, thereby driving a form of inflammatory cell death called pyroptosis. NLRP3 plays an important role in a variety of inflammatory diseases, including metabolic and cardiovascular disorders. Currently, there is a significant unmet clinical need in the treatment of
About this update from Insilico Medicine Cayman Topco
[{"type":"list","items":[{"val":[{"type":"text","content":"NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source.","length":242,"tagName":"p"}]},{"val":[{"type":"text","content":"Unlike ISM8969, Insilico's brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency.","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Empowered by AI, ISM5059 demonstrated robust efficacy, excellent safety profiles in preclinical studies, and low predicted human efficacious dose, with high potential in multiple indications including autoimmune and chronic cardiometabolic diseases with no obvious CNS (central nervous system) related toxicity observed in preclinical studies.","length":343,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":776,"olType":false},{"type":"text","content":"HONG KONG, Feb. 5, 2026 /PRNewswire/ -- The NOD-like receptor protein 3 (NLRP3) inflammasome is a validated target for anti-inflammatory drug development. Upon activation by internal and external stimuli, NLRP3 mediates the release of proinflammatory cytokines IL-1β and IL-18, thereby driving a form of inflammatory cell death called pyroptosis. NLRP3 plays an important role in a variety of inflammatory diseases, including metabolic and cardiovascular disorders. Currently, there is a significant unmet clinical need in the treatment of systemic inflammatory diseases, highlighting the urgent demand for innovative drug options with greater efficacy and a wider safety margin.","length":684,"tagName":"p"},{"type":"text","content":"Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the nomination of ISM5059, an AI-empowered, peripherally restricted small molecule inhibitor targeting NLRP3 as preclinical candidate compound (PCC). Guided by Pharma.AI, Insilico's proprietary generative platform covering the whole cycle of drug discovery, ISM5059 features a novel core structure, was specifically designed to inhibit NLRP3 conformational changes and oligomerization, while maintaining exceptional safety profiles.","length":544,"tagName...